Scott L. Friedman MD, Icahn School of Medicine at Mount Sinai hospital, New York, USA

Dr. Friedman is Chief of Liver Diseases and Dean for Therapeutic Discovery at the Icahn School of Medicine at Mount Sinai.  His pioneering research in hepatic fibrosis supported by NIH since 1986, combined with mentoring of over 80 trainees have contributed to the emergence of fibrosis as an exciting new therapeutic area in hepatology. Dr. Friedman was a Senior Fulbright Scholar at the Weizmann Institute, Israel in 1995 and President of the AASLD in 2009.  He has received the International Hans Popper the EASL International Recognition Awards, the AASLD Distinguished Award and the American Liver Foundation Distinguished Award.  Dr. Friedman is a Fellow of the AASLD, AGA, ACP and AAAS.

Massimo Pinzani, MD, PhD, FRCP, FAASLD, University College London

Massimo Pinzani is Professor of Medicine at University College London (UCL), London, United Kingdom. He is a clinical and translational hepatologist, Sheila Sherlock Chair of Hepatology and Director of the UCL Institute for Liver and Digestive Health, Division of Medicine. He is one of the pioneers in the research dedicated to cellular and molecular mechanisms of liver fibrosis and relative diagnostic and therapeutic approaches. Current
research is centred on regenerative medicine and in particular on the development of extracellular matrix scaffold of liver, pancreas and small intestine for cell bioengineering and 3D disease modelling. Professor Pinzani research activity is summarised in more than 200 original peer-reviewed publications (H Index of 81, Scopus). He has served in the governing and scientific boards of major international organization in the area of Hepatology and
Gastroenterology, and as Editor in Chief and Associate Editor of top peer reviewed international journals in the area of Gastroenterology and Hepatology. He is Educational Councilor and member of the governing board of the European Association for the Study of the Liver (EASL). He is currently chairman and co-founder of Engitix Ltd, an UCL spin-off company dedicated to tissue engineering and regenerative medicine with particular focus on the liver and digestive tract.

Arun Sanyal, MD, The Virginia Commonwealth University in Richmond, Virginia, USA

Arun Sanyal, MD is a Professor of Medicine, Physiology and Molecular Pathology, Division of Gastroenterology, Hepatology and Nutrition at the Virginia Commonwealth University (VCU) School of Medicine. Dr. Sanyal is special Council Board Member of NIAAA (National Institute on Alcohol Abuse and Alcoholism) and has been a past President of the AASLD (American Association for the Study of Liver Diseases). He has chaired committees at the NIDDK NASH clinical research network and the NIH hepatobiliary study section. Dr. Sanyal was instrumental in establishing the international Liver Forum for NASH and continues to serve as a Chair of this organization comprising industry, academia and regulatory bodies from the USA and EU. Dr. Sanyal is also leading several major drug trials for the treatment of NASH. He has published over 300 papers in leading medical journals and periodicals throughout his career.

Dr. Eric Gershwin, MD,MACP,MACR,  The University of California, Davis California, USA

Dr. M. Eric Gershwin is Distinguished Professor of Medicine as well as the Jack and Donald Chia Professor of Medicine. He is also Chief of the Division of Allergy and Clinical Immunology at the University of California School of Medicine in Davis. He graduated from Stanford Medical School in 1971 and subsequently trained in internal medicine and then immunology at Tufts University-New England Medical Center and the National Institutes of Health. He joined the UC Davis faculty in 1975 and has been Division Chief since 1982 and has been continuously funded by NIH since 1975 and currently has published more than 20 books, 800 experimental papers, and 200 book chapters or review articles. He is triple-boarded in rheumatology, allergy-immunology and internal medicine. He is editor-in-chief of the Journal of Autoimmunity and also Clinical Reviews in Allergy and Immunology and on the editorial board of multiple other journals. Gershwin is listed in the top 1% of all cited authors in Pubmed in immunology and has sat and chaired on committees for NIH, NSF, USDA, FTC and the FDA. He is an authority on autoimmune liver disease and was the first person to clone an autoantigen, the immunodominant mitochondrial autoantigen of primary biliary cholangitis.